NCT06619288View on ClinicalTrials.gov

Good-first: B/F/TAF As First-line ART

RecruitingOBSERVATIONAL
Enrollment

630

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
HIV Infection
Interventions
DRUG

B/F/TAF

Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.

DRUG

TDF+3TC+EFV

Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).

DRUG

DTG/3TC

Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.

Trial Locations (1)

226006

RECRUITING

Nantong Third Peoples Hospital, Nantong

All Listed Sponsors
collaborator

Nantong Third Peoples Hospital

UNKNOWN

lead

Affiliated Hospital of Nantong University

OTHER